ImmunoCAP

The technology used in the ImmunoCAP platform enables a high binding capacity per mg cellulose in combination with an optimal amount of cellulose in each solid phase. This ensures binding of all relevant antibodies, regardless of antibody affinity, still giving low non-specific binding. The ImmunoCAP solid phase consists of a cellulose derivative enclosed in a capsule. The hydrophilic, highly branched polymer provides an ideal microenvironment for allergens, binding them irreversibly while maintaining their native structure.

The test is designed as a sandwich immunoassay. Biotinylated drug, bound to streptavdine-coated solid phase, reacts with the drug-specific IgE in the patient serum sample. After washing, enzyme-labeled antibodies against IgE are added to form a complex. After incubation, unbound enzyme-labeled anti-IgE is washed away and the bound complex is then incubated with a developing agent. After stopping the reaction, the fluorescence of the eluate is measured. The fluorescence is directly proportional to the concentration of IgE in the serum sample.